Kobayashi K, Nakata M, Terazono H, Shinsato T, Saheki T
Department of Biochemistry, Faculty of Medicine, Kagoshima University, Japan.
FEBS Lett. 1995 Sep 18;372(1):69-73. doi: 10.1016/0014-5793(95)00948-9.
Deficiency of argininosuccinate synthetase (ASS) causes citrullinemia. Type II citrullinemia is found in most patients with adult-onset citrullinemia in Japan, and ASS is deficient specifically in the liver. Previous studies have shown that the decrease of hepatic ASS activity is caused by a decrease in enzyme protein with normal kinetic properties and that there are no apparent abnormalities in the amount, translational activity, and nucleotide sequence of hepatic ASS mRNA. Recent results of homozygosity testing indicate that the primary defect of type II citrullinemia is not within the ASS gene locus. In this present work, to understand the pathogenesis and pathophysiology of type II citrullinemia, we have characterized the alterations of gene expression in the liver of type II patients using the recently developed mRNA differential display method. Some cDNA bands expressed differently in type II citrullinemia patients and control were selected, cloned, and sequenced. Nucleotide sequence analysis and homology searching revealed an interesting clone which has 99% homology with the human pancreatic secretory trypsin inhibitor (hPSTI). Northern blot and RT-PCR analyses showed that the expression of hPSTI mRNA increased significantly in the liver of all type II patients tested. Furthermore, the concentration of hPSTI protein was found to be higher in the liver of type II citrullinemia than in control. These results suggest that hPSTI may be related to the primary defect of type II citrullinemia and may be useful as a diagnostic marker, although the detailed mechanism of the high expression of hPSTI mRNA in type II liver is not yet known.
精氨琥珀酸合成酶(ASS)缺乏会导致瓜氨酸血症。在日本,大多数成人型瓜氨酸血症患者患有II型瓜氨酸血症,且ASS在肝脏中特异性缺乏。先前的研究表明,肝脏ASS活性降低是由具有正常动力学特性的酶蛋白减少所致,并且肝脏ASS mRNA的量、翻译活性和核苷酸序列没有明显异常。纯合性检测的最新结果表明,II型瓜氨酸血症的主要缺陷不在ASS基因位点内。在本研究中,为了了解II型瓜氨酸血症的发病机制和病理生理学,我们使用最近开发的mRNA差异显示方法对II型患者肝脏中的基因表达变化进行了表征。选择了一些在II型瓜氨酸血症患者和对照中表达不同的cDNA条带,进行克隆和测序。核苷酸序列分析和同源性搜索揭示了一个有趣的克隆,它与人类胰腺分泌性胰蛋白酶抑制剂(hPSTI)具有99%的同源性。Northern印迹和RT-PCR分析表明,在所有检测的II型患者肝脏中,hPSTI mRNA的表达显著增加。此外,发现II型瓜氨酸血症患者肝脏中hPSTI蛋白的浓度高于对照。这些结果表明,hPSTI可能与II型瓜氨酸血症的主要缺陷有关,并且可能作为一种诊断标志物有用,尽管II型肝脏中hPSTI mRNA高表达的详细机制尚不清楚。